UC Irvine

UC Irvine Previously Published Works

Title

Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.

Permalink

<https://escholarship.org/uc/item/7qc1t62d>

Journal

Clinical and experimental nephrology, 18(2)

ISSN

1342-1751

Author

Vaziri, Nosratola D

Publication Date

2014-04-01

DOI

10.1007/s10157-013-0847-z

Peer reviewed

Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease

Nosratola D. Vaziri

Clinical and Experimental Nephrology

Official Publication of the Japanese Society of Nephrology

ISSN 1342-1751

Volume 18

Number 2

Clin Exp Nephrol (2014) 18:265-268

DOI 10.1007/s10157-013-0847-z

Your article is protected by copyright and all rights are held exclusively by Japanese Society of Nephrology. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease

Nosratola D. Vaziri

Received: 12 June 2013 / Accepted: 22 July 2013 / Published online: 24 August 2013
© Japanese Society of Nephrology 2013

Abstract Advanced chronic kidney disease (CKD) results in a constellation of dysregulation of lipid metabolism, oxidative stress, and inflammation which are causally interconnected and participate in a vicious cycle. The CKD-associated lipid disorders are marked by impaired clearance of very low density lipoprotein and chylomicrons, hypertriglyceridemia, formation of small dense low-density lipoprotein (LDL), oxidative modification of LDL, intermediate density lipoprotein and chylomicron remnants, and high-density lipoprotein deficiency and dysfunction. This review provides a brief overview of the role of CKD-induced lipid disorders in the pathogenesis of oxidative stress, inflammation, cardiovascular disease, impaired exercise capacity, cachexia and wasting syndrome.

Keywords End-stage renal disease · Oxidative stress · Impaired exercise capacity · Skeletal muscle · Adipose tissue · Lipid metabolism · Malnutrition

Background

Advanced chronic kidney disease (CKD) results in a triad of oxidative stress, inflammation and dyslipidemia which form a vicious circuit that promotes progression of kidney disease, cachexia, diminished exercise capacity, cardiovascular disease, and numerous other complications [1]. Patients with end-stage renal disease (ESRD) maintained on hemodialysis have elevated serum triglyceride, very

low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), chylomicron remnants, and oxidized lipoproteins. This is frequently accompanied by reduced plasma ApoA1 and high-density lipoprotein (HDL) cholesterol concentrations, and low or normal serum total cholesterol and low-density lipoprotein (LDL) cholesterol concentrations [2–4]. LDL in these patients consists of highly atherogenic small dense particles which contain abnormal levels of residual triglycerides [4–6]. In addition serum level of lipoprotein(a) [Lp(a)], particularly its low molecular forms is increased and contributes to cardiovascular disease in this population [7]. However, due to concomitant genetic or other disorders a minority of ESRD patients have elevated HDL and or LDL cholesterol levels.

Mechanisms of CKD-induced lipid/lipoprotein disorders

Nascent VLDL and chylomicrons are, respectively, packaged by the liver and intestine and released in the circulation for delivery of lipid fuels and construction material to the myocytes, adipocytes and various other cells for generation and storage of energy and incorporation into the cellular structures. Maturation of nascent VLDL and chylomicrons, lipolysis of their triglyceride cargos, conversion of IDL to LDL, and removal of chylomicron remnants by the liver are impaired in CKD [2–4]. Several factors contribute to these abnormalities. Maturation of the nascent VLDL and chylomicrons depends on acquisition of ApoC and ApoE from cholesterol ester-rich HDL-2 which are scarce in CKD [8]. Since ApoE is necessary for endothelial binding of VLDL and chylomicrons and ApoC-II is necessary for activation of lipoprotein lipase (LPL), their defective transfer from HDL limits lipolysis of triglyceride

N. D. Vaziri (✉)
Division of Nephrology and Hypertension, University
of California Irvine Medical Center, Suite 400, City Tower,
101 City Drive, Orange, CA 92868, USA
e-mail: ndvaziri@uci.edu

contents of VLDL and chylomicron. This is compounded by CKD-induced reduction in skeletal muscle, adipose tissue and myocardial LPL [9–11] which is, in part, due to down-regulation of the adaptor molecule glycosylphosphatidylinositol-anchored binding protein 1 (GPIHBP1) [12]. Consequently deficiencies of LPL and GPIHBP1 in CKD severely impair VLDL and chylomicron metabolism.

After undergoing lipolysis by LPL, VLDL and chylomicrons are transformed to IDL and chylomicron remnants and released into the circulation. Chylomicron remnants and a portion of IDL are then removed by the liver via LDL receptor-related protein (LRP) [13]. However, CKD results in down-regulation of hepatic LRP [14] leading to accumulation of oxidation-prone and atherogenic chylomicron remnants in the plasma.

Normally IDL is converted to cholesterol ester-rich LDL which is readily cleared by the liver via LDL receptor. The IDL conversion to LDL requires removal of its triglyceride cargo and expansion of its cholesterol ester content. This is accomplished by cholesteryl ester transfer protein (CETP)-mediated exchange of triglycerides for cholesterol ester between IDL and HDL2 and hydrolysis of the triglyceride and phospholipid contents of IDL by hepatic lipase. However, although serum CETP level is normal in ESRD patients [15], this process is impaired due to the scarcity of HDL-2 and hepatic lipase deficiency [16–18]. These abnormalities lead to accumulation of IDL and formation of CE-poor, triglyceride-rich small dense LDL which has low binding affinity for LDL receptor and is highly oxidation prone and atherogenic.

A fraction of plasma VLDL is cleared via VLDL receptor-mediated endocytosis by myocytes and adipocytes [19]. CKD results in down-regulation of skeletal muscle and adipose tissue VLDL receptor [20, 21] which can contribute to elevation of plasma VLDL.

Mechanisms of CKD-induced HDL abnormalities

In addition to its role in reverse cholesterol transport, normal HDL limits uptake of oxidized lipoproteins by macrophages, prevents monocyte adhesion/infiltration in the artery wall, exerts antioxidant and anti-inflammatory actions, facilitates endothelial repair and regeneration, and inhibits platelet adhesion. Via these actions, normal HDL protects against atherosclerosis, restores endothelial function, and attenuates oxidative stress and systemic inflammation. HDL cholesterol is reduced, maturation of CE-poor to CE-rich HDL-2 is impaired [8] and antioxidant, anti-inflammatory and reverse cholesterol transport activities of HDL are impaired in most ESRD patients [22, 23]. These abnormalities are due to (a) reduced production and oxidative modification of ApoAI [8, 24, 25] which lead to

HDL deficiency and impaired HDL binding to the gateway of cholesterol efflux (ATP binding cassette A1), (b) upregulation of acyl-CoA cholesterol acyltransferase (ACAT) [26–29] which limits release of intracellular cholesterol, (c) lecithin cholesterol acyltransferase (LCAT) deficiency [30] which impairs HDL maturation, and (d) paraoxonase and glutathione peroxidase deficiencies [28] which limit the ability of HDL to reduce oxidized LDL.

Under normal conditions, CE-rich HDL-2 unloads its cholesterol and triglyceride cargos in the liver by binding to the HDL docking receptor, scavenger receptor-B1 (SRB-1). In contrast the CE-poor HDL particles which constitute the majority of HDL particles in most ESRD patients have low affinity for SRB-1 and high affinity for the hepatic HDL endocytic receptor (ATP synthase beta) which mediates their removal and degradation [31]. Collectively these abnormalities contribute to HDL deficiency and dysfunction in CKD. In addition HDL-2 plays a major role in metabolism of chylomicrons and VLDL by donating ApoE and ApoC and by enabling CETP-mediated exchange of cholesterol ester for triglyceride which is essential for IDL conversion to LDL. Thus, CKD-induced abnormalities of HDL structure and function have a wide range of adverse consequences far beyond the impairment of the reverse cholesterol transport process.

Role of lipid disorders in wasting and impaired energy metabolism

In addition to causing hypertriglyceridemia, impaired clearance of triglyceride-rich lipoproteins contributes to cachexia, malnutrition, reduced exercise capacity, and altered energy metabolism in CKD patients [1]. In this context the CKD-induced LPL and VLDL receptor deficiencies limit the supplies of lipid fuel and construction material to the skeletal muscles, myocardium and adipose tissues [32]. Limitation of available lipid fuel can, in turn, contribute to muscle weakness, diminished exercise capacity and myocardial dysfunction which are common in CKD patients. Similarly the reduction in delivery of fatty acids to the adipose tissue limits the capacity to store energy and contributes to weight loss, wasting and cachexia in this population.

Role of dyslipidemia in oxidative stress and systemic inflammation

The scarcity of cholesterol ester-rich HDL together with LPL, hepatic lipase and LRP deficiencies in CKD leads to elevation of plasma IDL and chylomicron remnants and

generation of small dense LDL. The small dense LDL, chylomicron remnants, and IDL are highly prone to oxidation which is accelerated by the CKD-associated HDL deficiency and dysfunction and oxidative stress. This phenomenon accounts for elevated plasma oxidized LDL and lipid peroxidation products in CKD patients. Formation and accumulation of the oxidized forms of LDL, IDL, and chylomicron remnants, in turn, amplifies inflammation by binding to oxidized LDL receptor-1 (LOX-1), scavenger receptor A-1 (SRA-1) and oxidized phospholipid receptors on monocytes and macrophages, and the consequent release of pro-inflammatory cytokines and chemokines [33, 34]. By virtue of their presence in the circulating blood, these pro-inflammatory particles serve as vehicles which readily spread inflammation throughout the body. Moreover, via lipid peroxidation chain reaction, these floating oxidized particles contribute to dissemination of oxidative stress in the CKD patients. Therefore, the alteration of lipid metabolism contributes to CKD-associated systemic inflammation and oxidative stress which promote cardiovascular disease, CKD progression, anemia, cachexia, malnutrition and various other morbidities.

Role of lipid disorders in atherosclerosis

Patients with CKD exhibit accelerated atherosclerosis and cardiovascular disease which are the primary cause of death in this population [35, 36]. Besides the classic risk factors for atherosclerosis several other conditions influence the development of cardiovascular disease in CKD/ESRD patients. In particular, ESRD patients exhibit medial calcification of the arteries, arteriosclerosis, endothelial dysfunction, cardiomyocyte/capillary mismatch, dilated cardiomyopathy, myocardial fibrosis, and sudden cardiac death [37–39]. These events are primarily driven by phosphate retention, reduced nitric oxide availability (due to oxidative stress and elevation of asymmetrical dimethylarginine), hypertension, hypervolemia, electrolyte imbalance, myocardial ischemia and fibrosis, and drug toxicities among other conditions.

The primary cause of accelerated atherosclerosis in CKD is oxidative stress and inflammation [40]. In contrast to the general population low serum cholesterol level is associated with increased risk of cardiovascular disease and overall mortality [41] whereas higher serum total and LDL cholesterol values are associated with greater survival in the ESRD population [42]. The lack of the significant role of cholesterol level, per se, as a cause of atherosclerotic cardiovascular disease in the majority of the ESRD population is clearly illustrated by the failure of randomized clinical trials of various statins to lower cardiovascular

events in hemodialysis patients [43–45]. The association between low serum cholesterol with higher mortality in this population is undoubtedly related to systemic inflammation which has a cholesterol-lowering effect. Conditions that increase influx or impair efflux of cholesterol in the macrophages can lead to atherosclerosis and cardiovascular disease independent of plasma cholesterol level. The influx of cholesterol in the macrophages in the ESRD population is facilitated by oxidation of chylomicron remnants, IDL and small dense LDL and defective HDL antioxidant and anti-inflammatory properties. This is compounded by impaired HDL-mediated reverse cholesterol transport due to oxidation of apoA1 (which interferes with HDL binding to ABCA1, the gateway of cholesterol efflux), LCAT deficiency (which limits cholesterol carrying capacity of HDL), and upregulation of ACAT (which favors retention of cholesterol ester within the artery wall). The constellation of these abnormalities drives the relentless progression of the atherogenic process in CKD patients independent of plasma cholesterol level.

In conclusion, besides promoting cardiovascular disease the CKD-induced dysregulation of lipid metabolism plays a major role in the pathogenesis of oxidative stress, inflammation, CKD progression, impaired exercise capacity, cachexia, and wasting syndrome in this population.

References

1. Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. *Blood Purif*. 2011;31:189–96.
2. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. *Am J Physiol, Renal Physiol*. 2006;290:262–72.
3. Vaziri ND, Moradi H. Mechanism of dyslipidemia of chronic renal failure. *Hemodial Int*. 2006;10:1–7.
4. Kaysen GA. New insights into lipid metabolism in chronic kidney disease. *J Ren Nutr*. 2011;21(1):120–3.
5. Rajman I, Harper L, McPake D, et al. Low-density lipoprotein subfraction profiles in chronic renal failure. *Nephrol Dial Transplant*. 1998;13:2281–7.
6. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. *Am J Kidney Dis*. 2000;35:852–62.
7. Kronenberg F, Neyer U, Lhotka K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. *J Am Soc Nephrol*. 1999;10:1027–36.
8. Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. *Nat Rev Nephrol*. 2010;6(5):287–96.
9. Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. *Kidney Int*. 1990;37:854–8.
10. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. *Kidney Int*. 1996;50:1928–35.

11. Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. *Am J Physiol*. 1997;273:F925–30.
12. Vaziri ND, Yuan J, Ni Z, Nicholas SB, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is compounded by downregulation of endothelial GPIIb/IIIa expression. *Clin Exp Nephrol*. 2012;16:238–43.
13. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. *J Clin Invest*. 2001;108:779–84.
14. Kim C, Vaziri ND. Downregulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. *Kidney Int*. 2005;67:1028–32.
15. Pahl MV, Ni Z, Sepassi L, Vaziri ND. Plasma phospholipid transfer protein, cholesterol ester transfer protein and lecithin: cholesterol acyltransferase in end-stage renal disease. *Nephrol Dial Transplant*. 2009;24(8):2541–6.
16. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. *J Clin Invest*. 1996;97:2167–73.
17. Liang K, Vaziri ND. Downregulation of hepatic lipase expression in experimental nephrotic syndrome. *Kidney Int*. 1997;51:1933–7.
18. Sato T, Liang K, Vaziri ND. Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor deficiencies in focal glomerulosclerosis. *Kidney Int*. 2003;64:1780–6.
19. Takahashi S, Kawarabayashi Y, Nakai T, et al. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. *Proc Natl Acad Sci USA*. 1992;89:9252–6.
20. Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. *Kidney Int*. 1997;51:1761–5.
21. Sato T, Liang K, Vaziri ND. Downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. *Kidney Int*. 2002;61:157–62.
22. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. *J Am Coll Cardiol* (2012) pii: S0735-1097(12) 04651-7.
23. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. *In vitro* stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-I mimetic peptide. *Kidney Int*. 2009;76(4):437–44.
24. Moradi H, Said HM, Vaziri ND. Post-transcriptional nature of uremia-induced down-regulation of hepatic apolipoprotein A-I production. *Transl Res* PMID: 23219399, (2012).
25. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. *Curr Opin Cardiol*. 2006;21:322–8.
26. Liang K, Vaziri ND. Upregulation of Acyl-CoA: cholesterol acyltransferase (ACAT) in chronic renal failure. *Am J Physiol Endocrinol Metab*. 2002;283:E676–81.
27. Kim HJ, Moradi H, Vaziri ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. *Am J Physiol Renal Physiol*. 2009;296(6):F1297–306.
28. Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND. Reverse cholesterol transport pathway in experimental chronic kidney disease. *Am J Nephrol*. 2009;30:147–54.
29. Vaziri ND, Bai Y, Yuan J, Said H, Sigala W, Ni Z. ApoA-I mimetic peptide reverses uremia-induced up-regulation of pro-atherogenic pathways in the aorta. *Am J Nephrol*. 2010;32(3):201–11.
30. Vaziri ND, Liang K, Parks JS. Downregulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. *Kidney Int*. 2001;59:2192–6.
31. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Tercé F, Collet X, Perret B, Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. *Nature*. 2003;421:75–9.
32. Adams G, Vaziri ND. Skeletal muscle dysfunction in chronic renal failure: effect of exercise. *Am J Physiol Renal Physiol*. 2006;290:783–91.
33. Glass CK, Witztum JL. Atherosclerosis: the road ahead. *Cell*. 2001;104:503–16.
34. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. *Circulation*. 2000;101:2889–95.
35. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351:1296–305.
36. Collins AJ, Foley R, Herzog C, et al. Excerpts from the US renal data system 2007 annual data report. *Am J Kidney Dis*. 2008;51: S1–320.
37. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. *J Am Soc Nephrol*. 2004;15 (Suppl. 1):S77–80.
38. Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. *Nat Rev Nephrol*. 2010;6:723–35.
39. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. *Nephrol Dial Transplant*. 2000;15(2): 218–23.
40. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter. *Nephrol Dial Transplant*. 2002;17(Suppl 11):28–31.
41. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. *JAMA*. 2004;291:451–9.
42. Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. *J Am Soc Nephrol*. 2007;18:293–303.
43. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med*. 2005;353:238–48.
44. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med*. 2009;360:1395–407.
45. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomized placebo-controlled trial. *Lancet*. 2011;377:2181–92.